Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control label Clear all
Recruiting Phase 3 Interventional

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

NCT06575192
View directory record Official record
Conditions
Breast Reconstruction
Interventions
ARTIA Reconstructive Tissue Matrix
Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571
View directory record Official record
Conditions
NASH/MASH, NAFLD/MASLD
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
139
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

NCT04146363
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
30
States / cities
Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

NCT03486392
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 1:37 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism

NCT01887132
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Donepezil, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
24 Months to 50 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Metabolic Health Study

NCT06790407
View directory record Official record
Conditions
Healthy
Interventions
Mimio Study Product, Placebo
Dietary Supplement
Lead sponsor
Mimio Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 21, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

Auricular Acupressure in Prehabilitation

NCT06516198
View directory record Official record
Conditions
Frailty, Thoracic, Prehabilitation, Lung Surgery, Wedge Resection, Segmentectomy, Lobectomy, Pneumonectomy; Status
Interventions
Auricular Acupressure
Other
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 21, 2026, 1:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents

NCT04201106
View directory record Official record
Conditions
Depression
Interventions
Open Label Placebo with Rationale, Open Label Placebo without Rationale
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Not applicable Interventional

DermACELL in Subjects With Chronic Wounds of the Lower Extremities

NCT01970163
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
DermACELL, GraftJacket, Conventional Care Dressings
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Montgomery, Alabama • Tucson, Arizona • Carlsbad, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 21, 2026, 1:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

NCT04432584
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Crovalimab, Eculizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Food Swaps to Improve the Healthfulness and Reduce the Carbon Footprint of Grocery Purchases

NCT06648226
View directory record Official record
Conditions
Food Selection, Nutrition, Food Preferences, Dietary Habits, Sustainability, Healthy Diet
Interventions
Health swaps, Climate swaps, Combined health and climate swaps, Control
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038
View directory record Official record
Conditions
Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT00500149
View directory record Official record
Conditions
ADHD
Interventions
Vyvanse (lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
9
States / cities
Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 1:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents

NCT00369967
View directory record Official record
Conditions
Contraception Desired
Interventions
NuvaRing
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 21 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

NCT03168828
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Troy, Michigan • Charlotte, North Carolina • Virginia Beach, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 21, 2026, 1:37 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

NCT05132881
View directory record Official record
Conditions
Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions
Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 1:37 PM EDT